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1 Model of life-expectancy
Mortality on ART has been shown to depend strongly on age and CD4 cell
count at initiation [1, 4]. We construct a life-expectancy at ART initiation
that follows the general patterns described in [1], while allowing flexible vari-
ation. We take life-expectancy on starting ART to be
LE =[60− a]+ × (τA/τm)γ
=[60− a]+ ×
(
CD4A
CD41
)γ
(1)
where [X]+ = max(X, 0), and where CD4A and CD41 are points in CD4-
count schedule described in Section 2 and Figure 1B in the main text. This
means that those who state ART later, for a given age, live less long than
those who start early. More life-years are lost to later starts as γ increases.
For γ < 1, differences in CD4 counts for ART initiation have a greater impact
on survival at low CD4 counts than at high CD4 counts.
Figure 1 plots life-expectancies for different ages at ART starts for the
default γ = 0.5, and Figures 2a & 2b plot life-expectancies for the two
extremes of the range of γ considered (γ = 0.25 and γ = 1.00, respectively).
2 Model of TB risk and CD4 positive cell
count decline
We assume HIV-uninfected individuals have a CD4 cell count of 1000 cells/µL
and that, as in [3], this declines immediately by 25% upon HIV infection.
Their CD4 cell count is then assumed to decline linearly to death at τm.
Upon starting ART, an individual’s CD4 cell count is assumed to be
boosted by an amount ∆. In the main paper ∆ is chosen in conjunction
with the risk model of Section 4 to produce the required rate ratio for TB on
ART. Given our interest in the long-term, we caricature an increase that in
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Figure 1: γ = 0.5.The default life-expectancy on starting ART, as a function
of age and CD4 cell count.
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(a) γ = 0.25
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(b) γ = 1
Figure 2: Alternative scenarios for life-expectancy starting ART.
reality occurs over a few years [2] after starting ART as instantaneous. The
CD4 level achieved and the associated protection from TB should therefore
be characteristic of a patient on ART once this initial rise has taken place.
A linear decline over the individual’s lifetime on ART is assumed to re-
sult in the loss of a fraction f of this new CD4 count at time of death τ ′m,
due to immunologic failure, imperfect adherence, or other reasons. f = 1
corresponds to our ‘pessimistic’ scenario, wherein an individual’s CD4 count
declines to zero, although at a slower rate than untreated individuals. f = 0
corresponds to our ‘optimistic’ scenario, wherein the level of CD4 reconstitu-
tion and protection from TB are maintained throughout an individual’s life,
until death at τ ′m.
This implies:
CD4A =CD41
τm − τA
τm
(2)
CD41 =
3
4
CD40 (3)
CD42 =CD4A + ∆ (4)
CD4(τ) =
 CD41
[
τm−τ
τm
]
+
if 0 < τ < τA or off-ART
(1− f).CD42 + f.CD42 τ ′m−ττ ′m−τA if on ART & τ ≥ τA
(5)
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3 HIV/ART model
Figure 1A in the main text summarizes the logic of the model. Individuals
are either in class I - infected with HIV, not on ART; or class A - infected
with HIV, on ART. New individuals enter the model on the left at a rate
that may vary with calendar time, and propagate rightwards. Those who are
not started on ART die at point τm, whereas those who are started on ART
transit to class A at point τA and die at a later point τ
′
m. The mathematical
details are described in the sequel.
3.1 HIV only
Let I(t, a, τ ; τm) be the number of individuals at time t that are aged a,
where infected with HIV time τ ago, are not on ART and who will die a time
τm after their initial infection in the absence of treatment. This quantity
satisfies the partial differential equation
(
∂
∂t
+
∂
∂τ
+
∂
∂a
)
I(t, a, τ ; τm) = −µ(τ)I(t, a, τ ; τm), (6)
where the mortality is defined in terms of a Dirac delta function enforcing
death τm years after infection:
µ(τ) = δ(τ − τm), (7)
and with boundary condition
I(t, a, 0; τm) = i(t)φ(a)P (τm). (8)
Here, i(t) is the HIV incidence at calendar time t, φ(a) represents the distri-
bution of ages at HIV infection, and P (τm) the distribution of life-expectancy
at HIV-infection in the absence of treatment. The distributions P and φ are
modelled as Weibull distributions (as described in the main text), and aver-
ages over these distributions performed as described later in this document.
Defining
θ(x) =

1 if x > 0
1
2
if x = 0
0 otherwise
(9)
Equations 6 & 8 can be solved by the method of characteristics to give
5
I(t, a, τ ; τm) =I˜(t, a, τ ; τm)θ(τm − τ) (10)
I˜(t, a, τ ; τm) =I˜(t− τ, a− τ, 0; τm)θ(t− τ)
+ I˜(0, a− t, τ − t; τm)θ(τm − τ) (11)
with
I˜(t, a, 0; τm) = i(t)φ(a)P (τm) (12)
and I˜(0, a, τ ; τm) determined by the initial condition.
3.2 ART population
We imagine that a proportion V (t) at time t of those reaching a threshold
time-since-infection τ = τA(τm) commence ART. The dependence of τA on τm
allows this threshold to be specified in terms of a CD4 cell count threshold,
given a model that determines CD4 cell count in terms of τ and τm, like
Equation 5. We assume that a new time of death τ ′m is determined by the
age, a, time of ART commencement, τA, and original time of death τm.
Given our dependence of τA on τm, we can treat the new time of death as a
function τ ′m(a, τm). Analogously to Equation 6, A(t, a, τ ; τm), the number of
individuals on ART at time t with age a, who were HIV-infected a time τ
ago, and with time of death without ART τm, satisfies
(
∂
∂t
+
∂
∂τ
+
∂
∂a
)
A(t, a, τ ; τm) = −µA(τ)A(t, a, τ ; τm), (13)
with
µA(τ) = δ(τ − τ ′m) (14)
and
A(t, a, τA; τm) = V (t)I(t, a, τA; τm) (15)
with the right hand side of Equation 15 understood to be evaluated with τ
just less than τA and imposing A(t, a, τ ; τm) = 0 for τ < τA.
6
3.3 Combined solution
If at t = 0 no-one is on ART, the overall solution for A and I is specified by
I(t, a, τ ; τm) =
{
I˜(t, a, τ ; τm)θ(τm − τ) if τ ≤ τA
(1− V (t− τ + τA))I˜(t, a, τ ; τm)θ(τm − τ) if τ > τA
(16)
I˜(t, a, τ ; τm) =I˜(t− τ, a− τ, 0; τm)θ(t− τ)
+ I˜(0, a− t, τ − t; τm)θ(τm − τ) (17)
A(t, a, τ ; τm) =A(t− τ + τA, a− τ + τA, τA; τm)
× θ(τ ′m(a− τ + τA, τm)− τ) (18)
and
A(t− τ + τA, a− τ + τA, τA; τm)
= V (t− τ + τA)I˜(t− τ + τA, a− τ + τA, τA; τm) (19)
= V (t− τ + τA)×
[I˜(t− τ, a− τ, 0; τm)θ(t− τ) + I˜(0, a− t, τ − t; τm)θ(τ − t)] (20)
with the boundary condition for I˜ specified by Equation 8.
3.4 Starting from equilibrium
If the system begins at equilibrium at t = 0 with HIV incidence equal to i0,
a constant birth-rate, and no-one on ART, and thereafter the HIV incidence
follows Equation 8, then this solution becomes
I˜(t, a, τ ; τm) =P (τm)φ(a− τ)[i(t− τ)θ(t− τ) + i0θ(τ − t)] (21)
I(t, a, τ ; τm) =I˜(t, a, τ ; τm)θ(τm − τ)θ(τA − τ)
+ (1− V (t− τ + τA))I˜(t, a, τ ; τm)θ(τm − τ)θ(τ − τA) (22)
A(t, a, τ ; τm) =V (t− τ + τA)P (τm)φ(a− τ)θ(τ ′m(a− τ + τA, τm)− τ)
× [i(t− τ)θ(t− τ) + i0θ(τ − t)]θ(τ − τA) (23)
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Figure 3: Risk Model: the bold line shows the evolution of the incidence risk
ratio of developing TB for an individual who would have lived to time τm,
but starts ART at τA and has their life extended to τ
′
m. Significance of the
hatched areas is described in Section 4.1.
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4 TB incidence
We will take the hazard ratio for developing incident TB to be different
according to whether on or off ART, and functions of τ and τm (τ
′
m for those
on ART), denoted: hH(τ, τm) and hA(τ, τ
′
m) respectively. Let H denote the
respective cumulative hazards.
The total TB incidence in those infected with HIV, D˙(t) is given by
D˙(t) =
(
D˙H(t) + D˙A(t)
)
(24)
D˙H(t) =
∫ ∞
0
dτmP (τm)dH(t, τm) (25)
D˙A(t) =
∫ ∞
0
dτmP (τm)dA(t, τm) (26)
dH(t, τm) =
∫ ∞
0
da
∫ a
0
dτI(t, a, τ ; τm)hH(τ, τm) (27)
dA(t, τm) =
∫ ∞
0
da
∫ a
0
dτA(t, a, τ ; τm)hA(τ, τ
′
m(a− τ + τA, τm)) (28)
4.1 Equilibrium incidence
We calculate the new equilibrium reached after the introduction of ART,
when HIV incidence is constant. Writing i(0) = i0, and V¯ = (1− V ) for the
proportion not starting ART, and using Equations 21 & 22, dH becomes
dH(t, τm)/i0 =
∫ ∞
0
dτθ(τm − τ)[θ(τA − τ) + V¯ (t− τ + τA)θ(τ − τA)]hH(τ, τm)
=
∫ τA
0
dτhH(τ, τm) +
∫ τm
τA
dτV¯ (t− τ + τA)hH(τ, τm)
= HH(τA, τm) +
∫ τm
τA
dτV¯ (t− τ + τA)hH(τ, τm) (29)
since
∫
da.φ(a) = 1.
Similarly, using Equation 23, dA(t, τm) becomes
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dA(t, τm)/i0 =
∫
dadτA(t, a, τ ; τm)hA(τ, τ
′
m(a− τ + τA, τm))
=
∫
da
∫
dτhA(τ, τ
′
m(a− τ + τA, τm))
× V (t− τ + τA)φ(a− τ)θ(τ − τA)
=
∫ ∞
0
dxφ(x)
∫ τ ′m∧(t+τA)
τA
dτhA(τ, τ
′
m(x+ τA, τm))V (t− τ + τA) (30)
where we have used the substitution x = a − τ , and used the shorthands
τ ′m = τ
′
m(x+ τA, τm) and a ∧ b = min(a, b).
After a long time (∼ 20 years, see Figure 1(c) in the main text), if V (t)
tends to the value V , the sum of dA and dH from Equations 29 & 30 becomes
(up to an overall factor of i0):
HH(τA, τm) + (1− V ).(HH(τm, τm)−HH(τA, τm))
+ V.
∫ ∞
0
dxφ(x) [HA(τ, τ
′
m)]
τ ′m
τA
(31)
with τ ′m = τ
′
m(x+ τA, τm). This is easily interpreted in terms of areas under
portions of the hazard curves in Figure 3: the first term is the area under the
curve up to τ = τA; the second term is (1−V ) times the area under the curve
from τA to τm; the last term is V times an age-average of the area under the
ART hazard curve from τA to τ
′
m. It is thus clear that the equilibrium TB
incidence will be higher after ART roll-out when the population mean of the
forward-hatched area exceeds the mean of the backward-hatched area.
4.2 Specific solution
Following [3], we take TB risk to depend exponentially on the decline in CD4
cell counts:
h(τ) = exp [ρ˜(CD40 − CD4(τ))] (32)
with ρ˜ = 0.36 per 100 CD4 cells/µL lost.
The TB incidences in the model depend directly only on the model of haz-
ard ratios through time (i.e. Figure 3). We have arrived at these via a model
of CD4-decline and the an assumption that CD4 cell count exponentially
influences the rate of TB in the same way for HIV-infected individuals re-
gardless of whether they are on ART. For the model of CD4 cell count decline
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Figure 4: The coverage function for ART, V (t), with  = 5 years.
specified by Equation 5, our hazards are exponential in time-since-infection,
τ :
hH(τ, τm) = h0. exp(ρτ/τm) (33)
hA(τ, τ
′
m) =α.h0. exp(ρ
′τ) (34)
We will also take V (t) to be:
V (t) = V.θ(t)(1− e−t/) (35)
illustrated for  = 5 years in Figure 4, and HIV incidence to be declining at
a rate r for t > 0:
i(t) = i0.e
−rt (36)
Then, from Equation 27
dH(t, τm)/i0 =
∫ τm
0
dτ [1− V.θ(τ − τA)θ(t− τ + τA)(1− e−(t−τ+τA)/)]
× [e−r(t−τ)θ(t− τ) + θ(τ − t)]hH(τ, τm)
11
= h0
∫ τm∧t
0
dτeρτ/τme−r(t−τ) + h0
∫ τm∨t
t
dτeρτ/τm
+ h0V
∫ τm∧t
τA
dτeρτ/τme−r(t−τ)e−(t−τ+τA)/ + h0.V
∫ τm∧(τA+t)
τA∨t
dτeρτ/τme−(t−τ+τA)/
− h0V
∫ τm∧t
τA
dτeρτ/τme−r(t−τ) − h0.V
∫ τm∧(τA+t)
τA∨t
dτeρτ/τm
= h0e
−rt
[
e(ρ/τm+r)τ
(ρ/τm + r)
]τm∧t
0
+ h0
[
e(ρ/τm)τ
(ρ/τm)
]τm∨t
t
+ h0V e
−(t+τA)/−rt
[
e(ρ/τm+1/+r)τ
(ρ/τm + 1/+ r)
]τm∧t
τA
+ h0.V e
−(t+τA)/
[
e(ρ/τm+1/)τ
(ρ/τm + 1/)
]τm∧(τA+t)
τA∨t
− h0V e−rt
[
e(ρ/τm+r)τ
(ρ/τm + r)
]τm∧t
τA
− h0.V
[
e(ρ/τm)τ
(ρ/τm)
]τm∧(τA+t)
τA∨t
(37)
where it is understood that the integrals and square brackets evaluate to zero
when the top limit is smaller than the bottom, i.e.
[X(t)]ba =
{
X(b)−X(a) if a < b
0 otherwise
(38)
and where a ∨ b = max(a, b).
The contribution to TB incidence from those on ART is similarly given
by
dA(t, τm) =
∫ ∞
0
dx.φ(x)q(x) (39)
where
12
q(x) =∫
dτV (t− τ + τA)θ(τ − τA)θ(τ ′m − τ)hA(τ, τ ′m)[e−r(t−τ)θ(t− τ) + θ(τ − t)]
= V αh0
∫ z
τA
dτ(1− e−(t−τ+τA)/)e−r(t−τ)eρ′.τ
+ V αh0
∫ y
z
dτ(1− e−(t−τ+τA)/)eρ′.τ (40)
= V αh0e
−rt
[
e(ρ
′+r)τ
(ρ′ + r)
]z
τA
+ V αh0
[
eρ
′τ
ρ′
]y
z
− V αh0e−(t+τA)/−rt
[
e(ρ
′+1/+r)τ
(ρ′ + 1/+ r)
]z
τA
− V αh0e−(t+τA)/
[
e(ρ
′+1/)τ
(ρ′ + 1/)
]y
z
(41)
with τ ′m = τ
′
m(x+ τA, τm) and y = τ
′
m ∧ t and
z =

τA if t < τA
t if τA < t < y
y if y < t
(42)
or z = (t ∨ τA) ∧ y.
With the model of CD4 cell count decline described in Section 2, we have
hA(τ, τ
′
m) = exp
(
ρ˜CD40 − ρ˜(1− f)CD42 − f.ρ˜CD42 τ
′
m − τ
τ ′m − τA
)
=h0 exp
(
ρ˜CD41 − ρ˜(1− f)CD42 + f.ρ˜CD42 τ
′
m − τ
τ ′m − τA
)
(43)
where
h0 = exp[ρ˜(CD40 − CD41)] (44)
Comparing with Equation 34, we have
α = exp
[
ρ˜CD41 − ρ˜(1− f)CD42 − ρ˜f.CD42 τ
′
m
τ ′m − τA
]
(45)
ρ′ =f
ρ˜CD42
τ ′m − τA
(46)
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The unevaluated integrals in Equations 25, 26 & 39 can be calculated in
a Monte Carlo fashion by sampling τm and x from the distributions P and
φ respectively and taking the mean.
5 Supplementary results
In Figure 5 we display contour plots identical to Figure 1(d) in the main
paper, but including different ART initiation thresholds. The IRR, α, marked
with the horizontal dashed line corresponds to a protection from ART that
brings the TB rate just after ART initiation down to 4.4 times the general
population. The uncertainty envelopes arising from varying life-expectancy
become broader at low CD4 count since a fixed range of values for γ (see
Section 1) results in a larger percentage variation in life-expectancy for lower
ART initiation CD4 thresholds, i.e. the model of life-expectancy is more
sensitive to the parameter γ for late ART starts.
Figure 6 we display contour plots identical to Figure 1(d) in the main
paper, but mapping the regions where any subsequent peak in TB incidence
among people living with HIV is higher than the initial level.
6 Comparison of notation
In the main text γ is denoted p, α is denoted a, and l is used to represent
(τA/τm).
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